Cardinal Health (CAH) Stock
US healthcare distributor of drugs and medical products. Here's the price, business snapshot, and what's worth knowing about Cardinal Health in September 2026.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It’s Moving
Cardinal Health Eyes 13%-15% EPS Growth as Specialty Momentum Builds
- CEO Jason Hollar stated that all five operating segments are positioned for a 'constructive' period in fiscal 2027, targeting 13%-15% EPS growth following double-digit gains in fiscal 2026.
- The company is aggressively expanding its Management Services Organization (MSO) strategy through Solaris and other initiatives to scale physician networks and unlock growth in specialty care delivery.
- Comparative analysis suggests Cardinal Health holds an advantage over McKesson due to stronger estimate momentum and a more compelling specialty-led growth outlook.
Cardinal Health Eyes 13%-15% EPS Growth as Specialty Momentum Builds
- CEO Jason Hollar stated that all five operating segments are positioned for a 'constructive' period in fiscal 2027, targeting 13%-15% EPS growth following double-digit gains in fiscal 2026.
- The company is aggressively expanding its Management Services Organization (MSO) strategy through Solaris and other initiatives to scale physician networks and unlock growth in specialty care delivery.
- Comparative analysis suggests Cardinal Health holds an advantage over McKesson due to stronger estimate momentum and a more compelling specialty-led growth outlook.
Sixth Month Growth Performance
When is the next earnings date for CARDINAL HEALTH INC (CAH)?
Cardinal Health’s next earnings report is expected on October 29, 2026. It will cover the company’s first quarter of fiscal 2027, ending September 30, 2026. The date is consistent with CAH’s historical pattern of reporting first-quarter results in late October.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health stock as it has potential to increase in value.
Financial Health
Cardinal Health is generating substantial revenue and cash flow, but its profitability is relatively low.
Dividend
Cardinal Health's dividend yield of 0.93% is low, indicating limited returns from dividends. If you invested $1000 you would be paid $9.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
